PDS Biotechnology (PDSB) Free Cash Flow (2014 - 2025)
PDS Biotechnology's (PDSB) quarterly Free Cash Flow came in at -$3.7 million in Q4 2025, up 55.04% YoY from -$2.4 million in Q4 2024, and up 37.41% on a QoQ basis from -$5.9 million in Q3 2025.
PDS Biotechnology (PDSB) Free Cash Flow (2014 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Free Cash Flow data on file, last reported at -$3.7 million in Q4 2025.
- Quarterly Free Cash Flow rose 55.04% year-over-year to -$3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27.8 million (up 20.78% YoY) and the FY2025 annual result came in at -$27.8 million, up 20.84% from the prior year.
- Free Cash Flow grew to -$3.7 million in Q4 2025, from -$5.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $946225.0 in Q2 2021 to a low of -$13.2 million in Q1 2023.
- A 5-year average of -$6.7 million and a median of -$6.8 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2021 — Free Cash Flow soared 123.06% — and 2022, when it plunged 725.52%.
- Tracing PDSB's Free Cash Flow over 5 years: stood at -$4.5 million in 2021, then sank by 67.26% to -$7.5 million in 2022, then declined by 12.33% to -$8.5 million in 2023, then rose by 2.63% to -$8.2 million in 2024, then soared by 55.04% to -$3.7 million in 2025.
- The last three Free Cash Flow figures came in at -$3.7 million (Q4 2025), -$5.9 million (Q3 2025), and -$9.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.70 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -5.92 Mn |
| Sep 30, 2025 | -5.92 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Dec 31, 2024 | -8.23 Mn |
| Dec 31, 2024 | -8.23 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Mar 31, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.94 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Dec 31, 2023 | -8.46 Mn |
| Sep 30, 2023 | -7.18 Mn |
| Sep 30, 2023 | -7.18 Mn |